Table displaying the likelihood (risk ratio) of starting a new DMARD at the respective follow-up visits, comparing patients in inflammatory remission who reached, versus failed to reach, the treatment targets: (a) DAS28 remission=<2.6, (b) DAS28 low disease activity (LDA)=≤3.2, (c) SDAI remission=≤3.3, (d) SDAI LDA=≤11.0 and (e) ACR/EULAR Boolean remission
| Patients in inflammatory remission | 3 months RR (95% CI) | 6 months RR (95% CI) | 12 months RR (95% CI) | 24 months RR (95% CI) |
| DAS28 non-remission versus DAS28 remission | 1.14 (0.95 to 1.38) | 1.55 (1.25 to 1.91) | 1.51 (1.22 to 1.86) | 1.47 (1.20 to 1.81) |
| DAS28 non-LDA versus DAS28 LDA | 1.33 (1.05 to 1.69) | 1.74 (1.34 to 2.26) | 1.63 (1.23 to 2.16) | 1.68 (1.31 to 2.17) |
| SDAI non-remission versus SDAI remission | 1.27 (1.09 to 1.50) | 1.29 (1.04 to 1.58) | 2.01 (1.63 to 2.48) | 1.55 (1.29 to 1.88) |
| SDAI non-LDA versus SDAI LDA | 1.21 (0.93 to 1.58) | 2.23 (1.75 to 2.85) | 2.14 (1.66 to 2.77) | 1.77 (1.36 to 2.29) |
| Boolean non-remission versus Boolean remission | 1.28 (1.08 to 1.50) | 1.42 (1.14 to 1.77) | 1.77 (1.42 to 2.20) | 1.50 (1.23 to 1.82) |
The RR and 95% CIs are analysed by modified Poisson-regression, adjusted for age, sex and year of inclusion in SRQ (2011–2015 vs 2016–2020). The RR refers to the multiplicative effect on the ‘risk’ of starting a new DMARD at the follow-up visit for patients in inflammatory remission who failed to reach treatment targets, in reference to patients in inflammatory remission who reached the corresponding targets.
ACR, American College of Rheumatology; CI, confidence interval; DAS28, Disease Activity Score 28; DMARD, disease-modifying antirheumatic drug; EULAR, European Alliance of Associations for Rheumatology; RR, risk ratios; SDAI, Simplified Disease Activity Index; SRQ, European Alliance of Associations for Rheumatology.